Cannabis Treatment for Neuropathic Pain – Clinical Trials, Dosage, and Safety 2026

Neuropathic pain affects 6.9% to 10% of the general population in Europe, and in Poland it means about 2.5 million people with persistent, often drug-resistant ailments (Pain, 2014). Classic regimens based on gabapentin, pregabalin, duloxetine, or opioids fail in 30-50% patients or produce side effects that prevent continuation of therapy. Cannabis treatment for neuropathic pain fills this gap as a complement, and sometimes an alternative, to conventional therapy.

This guide dissects a retrospective study from the University Medical Center Hamburg-Eppendorf (n=99, mean NRS drop from 7.5 to 3.75), discusses the pathophysiology of neuropathic pain, the molecular mechanisms of CBD, THC, and CBG (CB1, CB2, TRPV1, 5-HT1A, alpha-2-adrenergic), the 2018 Cochrane data, dosing protocols, and the Polish reimbursement and regulatory landscape. Sources: PubMed, Cochrane Database, The Lancet Neurology, Pain, European Journal of Pain, IASP.

You'll learn when cannabis makes sense for diabetic neuropathy, postherpetic neuralgia, post-amputation phantom pain, chemotherapeutic polyneuropathy, and post-stroke central pain. We'll discuss interactions with gabapentin, pregabalin, duloxetine, amitriptyline, and opioids, as well as the principles of collaboration with a neurologist or pain physician. No promises, just research and clinical protocols.

What did the Hamburg study show about cannabis for neuropathic pain?

A retrospective study by a team from the University Medical Center Hamburg-Eppendorf included 99 German patients aged 20-81 years with chronic neuropathic pain and sleep problems (Medical Cannabis and Cannabinoids, Karger, 2023). The average pain level on the NRS scale decreased from 7.5 to 3.75 in the first six weeks of vaporization of medicinal herb with THC 12-22%, and 91% patients rated the therapy as well tolerated.

The protocol involved the inhalation of medicinal cannabis with a THC content of 12-22%, in daily doses ranging from 0.15 to 1 gram. The team collected data on pain intensity using the NRS scale, sleep disturbances, the patient's general condition, and tolerance of high doses of cannabinoids. The follow-up period lasted six months, with the first follow-up visit occurring in the sixth week of therapy.

The results were clearly distributed. At the beginning, 96% participants rated their pain above 6 on a 10-point scale, with an average of 7.5. After six weeks of cannabis therapy, the average dropped to 3.75, a reduction of half. At the first follow-up visit, 90% patients reported improvement in their overall condition, and at the peak of the study, as many as 99% (97 of 99 participants). Pain relief persisted until the end of the study.

What side effects did patients report?

No serious adverse events were reported during the six-month follow-up. Typical THC-related events, such as psychosis, tachycardia, respiratory depression, or severe impairment of vital functions, did not occur. Participants reported only mild symptoms: dry mouth in 5.4%, fatigue in 4.8%, and increased appetite in 2.7%.

In comparison, standard neuropathic pain medications have a significantly more severe side effect profile. Pregabalin caused dizziness in 29% patients, drowsiness in 22%, and weight gain in 12%, according to a 2019 Derry review (Cochrane Database of Systematic Reviews, 2019). Gabapentin causes drowsiness in 14% and dizziness in 19%. Opioids also carry a risk of addiction, respiratory depression, and constipation.

Sleep quality: second primary endpoint

Sleep disturbances are the most common symptom accompanying neuropathic pain. In the Hamburg study, participants reported improved sleep quality after the first few weeks of therapy, which persisted until the end of follow-up. The mechanism combines THC's direct effects on sleep stages, reduction of nocturnal pain, and modulation of the endocannabinoid system in the hypothalamus.

This is clinically significant because poor sleep quality further lowers the pain threshold (central sensitization). Breaking this loop—pain disrupts sleep, and sleep deprivation exacerbates pain—is one of the key goals of therapy. Data from Hamburg show that cannabis may fulfill this role more effectively than benzodiazepines or Z-drugs alone, which induce tolerance after 2-4 weeks.

Limitations of the study

The study has significant methodological limitations. It was not randomized, lacked a placebo group, was a retrospective analysis, was a small sample size (n=99), was a single center, and selected patients motivated to participate in cannabis therapy. Expectation and placebo effects may partially explain the magnitude of improvement. The authors themselves point to the need for randomized, controlled trials with long-term follow-up.

Nevertheless, the results are consistent with larger observational series, such as the German Schäfer 2021 registry (n=1030) and the Canadian CANWARD registry. In all of them, the NRS decline exceeds 2 points, which is considered a clinically significant difference by the IASP. The data do not replace RCTs but provide valuable information for Polish neurologists considering cannabinoid therapy.

Where does neuropathic pain come from and who does it affect?

Neuropathic pain results from damage or disease of the somatosensory part of the nervous system, as defined by the 2011 IASP (International Association for the Study of Pain, 2011). In Poland, it affects 6.9-10% of the adult population, i.e. about 2.5 million people, and in high-risk groups (diabetes, shingles, chemotherapy) the percentage reaches 25-50% of patients with the underlying disease.

Neuropathic pain is chronic and persistent. Patients describe it as burning, stinging, throbbing, stabbing, stabbing, or similar to an electric shock or stabbing. It can be continuous with flare-ups or intermittent. Its location does not necessarily coincide with the nerve injury; the pain often "radiates" to other areas of the body. This distinguishes it from nociceptive pain associated with tissue injury.

Pain-inducing stimuli can be mechanical, thermal, or chemical. Characteristic features of neuropathy include allodynia (pain induced by a normally painless stimulus, such as touching bedding) and hyperalgesia (an exaggerated pain response to a painful stimulus). These phenomena are markers of peripheral and central sensitization, processes that cannabis mechanistically targets.

Main causes of neuropathic pain

Neuropathic pain is a complex condition that encompasses a wide variety of clinical entities. Common causes of nervous system damage include:

• Diabetes: Diabetic neuropathy affects 50% people with type 2 diabetes after 10 years of disease, according to the ADA (Diabetes Care, 2017).
• Shingles: postherpetic neuralgia occurs in 10-18% patients after an episode of herpes zoster, the risk increases with age.
• Chemotherapy: paclitaxel-, oxaliplatin-, vincristine-, or bortezomib-induced polyneuropathy occurs in 30-68% treated patients.
• Injuries and amputations: phantom pain develops in 60-80% people after limb amputation.
• Autoimmune diseases: multiple sclerosis, Guillain-Barré syndrome, lupus.
• Viral infections: HIV, Hepatitis C, COVID-19 (increasing number of reports of post-covid neuropathies).
• Nerve entrapment: carpal tunnel syndrome, trigeminal neuralgia, sciatica.
• Toxic drugs: statins, amiodarone, isoniazid, metronidazole in chronic use.
• Environmental toxins: exposure to lead, mercury, arsenic, solvents.
• Kidney failure: uremic neuropathy in dialysis patients.
• Alcohol abuse: alcoholic neuropathy, often complicated by thiamine deficiency.
• Central pain: after stroke (approx. 8% patients), after spinal cord injuries (60-70%), in MS.

Not every nerve injury causes neuropathic pain. Predisposing mechanisms are multifactorial: genetic (SCN9A and COMT polymorphisms), demographic (age, gender), psychological (anxiety, depression, pain catastrophizing), and social. The development of neuropathic pain is a dynamic process involving neuroplasticity, peripheral sensitization, central sensitization, and changes in the somatosensory cortex.

Evaluation of the effectiveness of neuropathic pain therapy

Treatment effectiveness is measured multidimensionally, not just by a decrease in the NRS score. The IASP and EFNS recommend assessing four domains: pain intensity (NRS, VAS), sleep quality (PSQI, Insomnia Severity Index), mental status (HADS, Beck Depression Inventory), and subjective quality of life and functioning (SF-36, PROMIS). A decrease in the NRS score of at least 301 TP3T is considered a clinically significant response, and a decrease of 501 TP3T is considered a strong response.

In the Hamburg study, all four domains improved significantly, strengthening the interpretation of the results. The decrease in NRS alone could be due to placebo, but the simultaneous improvement in sleep, mood, and general well-being suggests a real pharmacological effect. This criterion is worth remembering when evaluating your own therapy: keep a journal of all four dimensions, not just pain.

How does cannabis work for neuropathic pain?

Hemp contains over 140 cannabinoids, the most researched of which are THC and CBD, with CBG, CBN, CBC and THCV gaining increasing attention (Frontiers in Pharmacology, 2020). In neuropathic pain, they act in multiple ways: they inhibit peripheral sensitization in nociceptors, modulate conduction in the spinal cord, and alter pain processing in the CNS. This explains why they work where gabapentin and opioids fail.

Neuropathic pain has a specific pathophysiology. The damaged nerve begins to generate spontaneous discharges (ectopic activity), axons "leak" signals to neighboring fibers (crosstalk), and the dorsal horns of the spinal cord become hyperexcitable (central sensitization). Microglia activate around the damaged neurons, releasing inflammatory cytokines. Each of these mechanisms is a therapeutic target of cannabis.

THC, CB1, and spinal analgesia

THC is an agonist at the CB1 receptor in the dorsal horn of the spinal cord, in the spinal ganglia, and in the rostral ventral glossopharyngeal nucleus (RVM) of the brainstem. CB1 activation inhibits the release of glutamate and substance P from afferent fibers, reducing the upstream transmission of pain signals. This mechanism is analogous to opioids acting on mu receptors, but without the risk of respiratory depression.

A study by Wallace et al. from UCSD on 16 patients with painful diabetic neuropathy showed a dose-dependent decrease in spontaneous pain with inhalation of THC 1%, 4%, and 7%, with a maximum reduction of approximately 30% on the VAS scale at the 7% dose (The Journal of Pain, 2015). The effect appeared in 5-15 minutes and lasted 2-4 hours.

CB1 is also present in the somatosensory cortex and amygdala. This explains THC's effect on the affective component of pain (suffering), not just the sensory component. Patients often say, "The pain is there, but it affects me less," which corresponds to the modulation of the emotional component by the endocannabinoid system.

CBD: TRPV1, 5-HT1A, PPARγ, FAAH

CBD does not bind directly to CB1 or CB2. It modulates at least 65 molecular targets, the most important for analgesia being TRPV1 (agonism with desensitization), 5-HT1A (agonism), PPARγ (activation of anti-inflammatory transcription), and the FAAH enzyme (inhibition of anandamide degradation). This polypharmacology explains its broad spectrum of action in various types of neuropathic pain.

The TRPV1 channel in peripheral nociceptors becomes sensitized in damaged nerves. CBD acts in two phases: initially stimulating the channel (hence the transient burning sensation with some CBD ointments), and then desensitizing it after several days of regular use. This effect reduces pain signal transmission from the periphery to the spinal cord, particularly in tactile and thermal allodynia.

5-HT1A agonism increases the activity of descending pain inhibitory pathways in the brainstem. This pathway is crucial in mixed pain with an anxiety or depression component, very common in fibromyalgia, diabetic neuropathy, and chronic pain following trauma. Activation of PPARγ reduces the production of proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6) in microglia and macrophages, slowing central sensitization.

CBG and alpha-2 adrenergic receptors

CBG (cannabigerol) is a lesser-known cannabinoid with a unique profile. It is an alpha-2 adrenergic receptor agonist, a 5-HT1A antagonist, and modulates TRPA1. Alpha-2 receptors are crucial for central pain control, which is why clonidine and tizanidine are often used for neuropathy. CBG replicates some of these effects without the risk of hypotension and sedation.

The study by Valdeolivas et al. showed neuroprotective and anti-inflammatory effects of CBG in an animal model of Huntington's disease and multiple sclerosis, with a reduction in microglial activation and improvement in motor function (Neurotherapeutics, 2015). In the context of neuropathy, this is important because microglia are the main cause of central sensitization in the CNS.

In clinical practice, CBG is often combined with CBD in a ratio of 1:3 to 1:1 for patients with diabetic neuropathy who do not respond to CBD alone. The additive mechanism through other receptor pathways may overcome tolerance to CBD monotherapy. There are no RCTs on this yet, but signals from preclinical studies and case registries are encouraging.

Entourage effect

Full-spectrum cannabis extracts contain cannabinoids, terpenes (beta-caryophyllene, myrcene, limonene, linalool, pinene), and flavonoids. The "entourage effect" hypothesis (Ben-Shabat and Mechoulam, 1998) posits that synergy between these compounds enhances analgesia and reduces side effects. Beta-caryophyllene is a selective CB2 agonist and has anti-inflammatory effects, linalool activates the adenosine receptor, and myrcene enhances cannabinoid penetration across the blood-brain barrier.

For neuropathic pain, beta-caryophyllene is of particular interest, as at a dose of 25 mg/kg in mice it reduced mechanical allodynia in a model of chemotherapeutic neuropathy by 40-50% (European Neuropsychopharmacology, 2014). This justifies the choice of full-spectrum or broad-spectrum extracts over CBD isolates in clinical practice.

What do the largest meta-analyses and Cochrane reviews say?

A 2018 Cochrane review (Mücke et al.) included 16 randomized trials with a total sample of 1750 patients with neuropathic pain and showed a clinically significant reduction in pain in 21% patients using cannabinoids versus 17% placebo, with an NNT of 20 and NNH (number to harm) of 25 (Cochrane Database of Systematic Reviews, 2018). The authors rated the quality of evidence as low to moderate, but the effect was consistent across multiple clinical settings.

Why is an NNT of 20 high or low? For comparison, pregabalin has an NNT of around 7-8 for diabetic neuropathy, and amitriptyline has an NNT of 4-5. Cannabinoids rank lower as monotherapy but are attractive as third-line therapy for patients whose first and second lines have failed or produce unacceptable side effects. These are not miracle cures, but complementary tools.

Sativex (nabiximols) for multiple sclerosis

Sativex is a nabiximols formulation containing CBD and THC in a 1:1 ratio, administered sublingually as a spray. It is registered in Europe for the treatment of spasticity and neuropathic pain in MS. The Leocani 2015 meta-analysis included 1,619 MS patients and showed a mean pain reduction of 1.8 points on the NRS versus 0.5 in placebo after 12 weeks of treatment (Multiple Sclerosis and Related Disorders, 2015).

Sativex is available in Poland, but not reimbursed, which limits availability. The monthly cost of therapy is 1800-2500 PLN for doses of 6-12 sprays per day. Alternatively, medicinal THC/CBD herbs from prescription-only pharmacies are available at RPW (Polish Registered Pharmacy) at a cost of 25-45 PLN per gram, which translates to 400-700 PLN per month for a dose of 0.5 g/day.

Mücke Review 2018 and Quality of Evidence

Mücke et al., in a 2018 Cochrane review, identified three categories of evidence. For nabiximols (Sativex), the evidence is moderate quality, with consistent effects in MS and peripheral neuropathy. For medicinal inhaled THC, the evidence is low, but the signal of effect is strong, primarily from small RCTs. For CBD isolate, the evidence in neuropathy is very limited, with most data coming from extrapolation from chronic pain.

The authors conclude that the potential benefits of cannabinoids may outweigh the risks in selected patients but require discussion with a physician. Side effects were more common in the cannabinoid group (drowsiness, dizziness, mental disturbances), but the incidence of serious adverse events was similar to that of placebo. This is important in the context of opioids, where the profile of serious effects is dramatically worse.

Newer data 2020-2024

Since the 2018 Cochrane publication, further RCTs and observational series have appeared. Aviram and Samuelly-Leichtag's 2017 meta-analysis included 43 RCTs with a total sample of 2,437 patients and showed a significant reduction in pain (SMD -0.63) compared to placebo, the greatest in central and peripheral neuropathy (Pain Physician, 2017).

The Wade 2022 study from the Quebec Pain Registry included 751 patients with chronic pain, including 285 with neuropathic pain. After 12 months of medical marijuana, 51% of the neuropathy patients had a decrease in NRS of at least 30%, and 32% reduced their opioid doses. This effect persisted for 24 months in 68% who continued treatment. This is one of the best databases of long-term cannabinoid efficacy in neuropathic pain.

When does cannabis make sense for specific neuropathies?

Not all neuropathies respond equally to cannabis. The strongest evidence is for diabetic neuropathy, postherpetic neuralgia, neuropathic pain in MS, phantom limb pain after amputation, and postchemotherapy polyneuropathy (Current Medical Research and Opinion, 2015). In each clinical setting, the cannabinoid profile and form of application may vary.

Diabetic neuropathy

Diabetic neuropathy is the most common form of neuropathic pain. It affects 50% in people with type 2 diabetes after 10 years of illness and 25% after 5 years. It most often affects the feet and lower legs, with a "gloves and socks" appearance. Standard treatments include pregabalin, duloxetine, and gabapentin as first-line therapies. Cannabis is considered a third- or fourth-line option if ineffective or intolerant.

The Wallace 2015 study (n=16) demonstrated the efficacy of inhaled THC 1-7% with a VAS reduction of approximately 30% at a dose of 7%. Nabiximols (Sativex) in diabetic neuropathy produced an NNT of approximately 8-10 in post-hoc analyses. Practical protocol: CBD 30-60 mg/d as a base, THC 2.5-5 mg/d (e.g., 0.1-0.2 g of dried herb per day) as a top-up, under the supervision of a diabetologist and neurologist. Slow titration, 7-10 days between dose changes.

Postherpetic neuralgia (PHN)

Postherpetic neuralgia occurs in 10-18% patients with herpes zoster and in 30-50% people over 70 years of age. The pain is burning, stinging, with tactile allodynia that significantly impairs function. The first-line treatments include amitriptyline, pregabalin, local lidocaine in 5% patches, and capsaicin in 8% patches.

Data for cannabis come primarily from subgroups of larger studies. Nabiximols, in post-hoc analyses by Ware 2010 and Berman 2004, resulted in a 2-3 point decrease in NRS in patients with PHN. Local CBD in the form of an ointment or balm supports local relief of allodynia when combined with capsaicin or lidocaine (not simultaneously, separated by 2 hours). Systemic preparations help with the seizure component and nocturnal pain.

Chemotherapy-induced polyneuropathy (CIPN)

CIPN is a complication in 30-68% cancer patients treated with paclitaxel, oxaliplatin, vincristine, or bortezomib. It manifests as numbness, tingling, and pain in the feet and hands, often interfering with daily activities. Standard medications (duloxetine, gabapentin) have moderate effectiveness.

Ward 2014 demonstrated the efficacy of CBD 1.5-5 mg/kg in an animal model of CIPN with oxaliplatin (Anesthesia and Analgesia, 2014). Human data are limited, but in observational registries, patients report improvement, particularly in the burning component and allodynia. Practical protocol: CBD 30-80 mg/d, with caution due to interactions with cytostatics via CYP3A4 and CYP2C9. Always in consultation with an oncologist.

Neuropathic pain in multiple sclerosis

This is the best-studied scenario, with Sativex approved in the EU. MS causes central neuropathic pain (from CNS damage) and muscle spasticity. Nabiximols reduces both components, with improvements in quality of life maintained with long-term treatment. In Poland, Sativex is available in pharmacies by prescription but is not reimbursed.

An alternative for patients who can't afford Sativex is prescription-strength medical-grade THC/CBD, vaporized at doses of 0.25-0.75 g/day. The effect occurs within 2-10 minutes, which is convenient for breakthrough pain. For sustained analgesia, CBD oil 5-10% at a dose of 40-100 mg/day provides a base, with vaporization serving as a temporary solution.

Phantom pain after amputation

Phantom limb pain develops in 60-80% individuals after limb amputation. The mechanism involves cortical reorganization in the somatosensory area and ectopic activity in the remaining nerves in the stump. Standard treatment (pregabalin, amitriptyline, mirror therapy) has moderate effectiveness.

A retrospective analysis of 37 veterans with phantom limb pain treated with medical marijuana showed a mean decrease in NRS from 6.8 to 4.2 after 8 weeks of therapy (Journal of Cannabis Research, 2021). The mechanism involves a reduction of central sensitization by CB1 in the somatosensory cortex and modulation of microglia around stump neurons.

Central pain after stroke and spinal cord injury

Central post-stroke pain (CPSP) occurs in approximately 8% patients and is particularly difficult to treat. Classical medications often fail. Data for cannabis are limited, but observational registries show partial efficacy in some patients. Neuropathic pain develops in 60-70% patients with spinal cord injury, and nabiximols reduced pain by 1.5 NRS points in the ROG 2005 study, compared with 0.8 for placebo.

What are the conventional treatments for neuropathic pain?

First-line drugs for neuropathic pain are gabapentinoids, SNRIs and TCAs, according to the guidelines of EFNS, NICE and the Polish Pain Society (The Lancet Neurology, 2015). Each of these groups has its own indications, side effect profile, and NNT, and cannabis is typically introduced as a third- or fourth-line therapy in patients refractory to first-line therapies.

Gabapentin and pregabalin

Gabapentinoids act by blocking the α2δ subunit of voltage-gated calcium channels in the presynaptic terminals of pain neurons. This reduces the release of glutamate, substance P, and CGRP. The NNT of gabapentin in neuropathy is 6-8, and of pregabalin 7-8. Therapeutic doses of gabapentin are 1200-3600 mg/d, and of pregabalin 150-600 mg/d.

Side effects include dizziness (19-29%), somnolence (14-22%), weight gain (12%), peripheral edema, and cognitive decline (Cochrane Database, 2019). The risk of falls is increased in older adults. Caution: Pregabalin and gabapentin have the potential for addiction, particularly in patient populations with a history of substance abuse.

Duloxetine and venlafaxine (SNRI)

SNRIs block serotonin and norepinephrine reuptake, enhancing descending pain inhibitory pathways in the brainstem. Duloxetine is approved for diabetic neuropathy at doses of 60–120 mg/day, with an NNT of 5–6. Venlafaxine at doses of 150–225 mg/day has comparable efficacy.

Side effects: nausea, dry mouth, insomnia, decreased libido, increased blood pressure. Beware of withdrawal symptoms upon abrupt discontinuation, requiring gradual dose reduction over 2-4 weeks. Interaction with tramadol and CBD may theoretically increase the risk of serotonin syndrome at high doses.

TCAs: amitriptyline and nortriptyline

Tricyclic antidepressants are the oldest medications used in neuropathy, with the highest NNT (4-5) for amitriptyline. Doses for neuropathy are lower than for depression (10-75 mg/day in the evening). The mechanism combines blockade of serotonin and norepinephrine uptake with action on sodium and NMDA channels.

Side effects are severe: sedation, dry mouth, constipation, urinary retention, weight gain, and QT prolongation. In individuals over 65 years of age, the risk of falls and cardiac arrhythmias limits its use. However, amitriptyline remains the "gold standard" in younger patients who tolerate the drug well, especially when insomnia is present.

Second-line drugs: lidocaine, capsaicin, tramadol

Lidocaine 5% patches, applied 12 hours a day, are effective for postherpetic neuralgia and neuropathy limited to a small area. The NNT for local pain is approximately 2, with a very good safety profile. Capsaicin 8% patches (Qutenza) provide 3 months of relief after a single in-office application, with an NNT of 7-10.

Tramadol is a second-line opioid with a dual mechanism (mu-agonism + serotonin and norepinephrine uptake inhibition). It has an NNT of 4-6 in neuropathy, but carries a risk of addiction, seizures, serotonin syndrome, and tachycardia. Strong opioids (morphine, oxycodone, fentanyl) are a third-line option, used in selected cases with careful titration.

Non-pharmacological methods

Standard treatment includes a multidisciplinary approach: physical therapy, psychotherapy (CBT, ACT), relaxation techniques, mindfulness, acupuncture for diabetic neuropathy, transcutaneous electrical nerve stimulation (TENS), and spinal cord stimulation (SCS) for selected, refractory cases. Nerve blocks and thermolesions are invasive techniques used in selected patients.

Cannabis is best suited to a multidisciplinary model, not as a monotherapy. Combining CBD with physiotherapy, an anti-inflammatory diet, and psychotherapy yields better results than either method alone. In Polish practice, this presents an organizational challenge, as reimbursed physiotherapy has long waiting lists, while private CBT is expensive.

How to dose cannabis for neuropathic pain?

There is no single protocol, the doses depend on the form of the preparation, the cannabinoid profile, the individual sensitivity of the patient and concomitant medications (Frontiers in Pharmacology, 2020). The "start low, go slow" rule is absolutely essential, especially for older individuals, those who are medically fragile, or taking multiple medications. Any escalation of 10-20 mg of CBD requires 5-7 days of observation.

CBD oral (oil, capsules)

Sublingual CBD oil is the standard for long-term systemic analgesia. Bioavailability: 13-19%, effect felt in 15-45 minutes, peak in 1-2 hours, duration: 4-6 hours. Starting dosage: 15-25 mg of CBD daily, divided into 2-3 doses. Titration: Add 10-15 mg every 5-7 days until clinical effect is achieved or 80-150 mg/day.

CBD capsules provide a stable concentration but act more slowly (60-120 minutes). Bioavailability is approximately 6-10% due to the first-pass effect in the liver. Recommended for patients who have difficulty tolerating the taste of the oil or require very stable exposure. Local forms (ointment, balm) complement systemic therapy for localized pain.

THC inhaled and oral

Medicinal herb vaporized at 180-210°C produces peak concentration in 5-10 minutes and an effect lasting 2-4 hours. Starting dosage: 0.05-0.1 g once daily (in the evening, due to psychoactive effects), which provides approximately 5-15 mg of THC with a 10-15% content. Escalation to 0.2-0.5 g/day under medical supervision. Maximum to 1 g/day for resistant analgesia, as in the Hamburg study.

Oral THC (medical marijuana oils, Sativex pre-packaged products) has a slower onset (60-120 minutes) and longer duration (6-8 hours), which is suitable for chronic pain and promotes nighttime sleep. Dosage: 1-2 sprays of Sativex (2.7 mg THC + 2.5 mg CBD each) every 4-6 hours, maximum 12 sprays/day. Titrate: 1 spray every 1-2 days until desired effect.

Vaporization of herbs for breakthrough pain

Attacks of neuropathic pain (trigeminal neuralgia, polyneuropathy exacerbations, phantom pain) require rapid analgesia. Vaporizing full-spectrum herb produces an effect within 2-10 minutes, which is ideal for this situation. The bioavailability of 30-50% is significantly higher than oral administration. The risk of lung damage is lower than with smoking, but not zero.

A practical strategy: 40-100 mg/day systemic CBD base + THC/CBD vaporizer as a "rescue dose." For breakthrough neuropathic pain, 2-3 inhalations of the herb (5-15 mg THC) produce results in 2-10 minutes. Limit to 3-4 sessions daily to avoid tolerance. Avoid in patients with asthma, COPD, or other respiratory conditions.

8-Week Neuropathy Protocol

We present a framework for implementing cannabinoids in patients with neuropathic pain, based on research protocols and clinical practice. The plan requires supervision by a neurologist or pain physician, and the doses are indicative and do not replace individual clinical assessment.

Week 0 (preparation): Keep a 7-day pain diary using the NRS scale, and record your sleep quality (PSQI), mood, and activity levels. Diagnose the cause of your neuropathy (HbA1c, B12, TSH, neurological tests). Consult your doctor about all medications, especially CYP3A4 and CYP2C9.

Week 1-2 (start): 20 mg CBD/d (10+10 mg sublingual) broad spectrum 5%. Titrate to 30-40 mg/d by the end of the second week. Do not change existing neuropathy medications. Monitor for drowsiness, dizziness, fatigue, and interactions.

Week 3-4 (CBD escalation): Increase to 50-80 mg CBD/d if effect insufficient. If pain has decreased by 30%+, stabilize. Consider adding a topical form for localized pain or CBG 15% (Cannova) 10-20 mg/d as a boost.

Week 5-6 (adding THC): If CBD alone isn't enough, after consulting your doctor (or with a prescription from a registered medical practitioner), introduce 0.05-0.1g of medicinal THC vaporized in the evening. Titrate to 0.2-0.5g/day, in 2-3 sessions daily, with a maximum at night for sleep.

Week 7-8 (assessment): Compare your pain diary to baseline. If your NRS has decreased by 30%+, continue. Consult your doctor about reducing your gabapentinoid or TCA dose if you experience drowsiness or dizziness from additive effects. Never stop suddenly.

What are the interactions of cannabis with neuropathic pain medications?

CBD inhibits cytochrome P450 enzymes CYP3A4, CYP2C9, and CYP2C19, which metabolize approximately 60% drugs used in neuropathy (Medical Cannabis and Cannabinoids, 2020). THC is metabolized by CYP2C9 and CYP3A4, so it competes for the same enzymes. This means combining cannabis with neuropathy medications requires caution but is not prohibited.

Rule of thumb: leave at least two hours between CBD and any drug metabolized by CYP450. During the first two weeks of combining, keep a diary of your symptoms (drowsiness, dizziness, blood pressure, heart rate). Report any changes to your doctor. If in doubt, ask for a blood level measurement (e.g., carbamazepine, valproate, lamotrigine).

Cannabis + gabapentin / pregabalin

The mechanisms don't overlap. Gabapentinoids act on α2δ channels, while cannabis acts on CB1/CB2 and TRPV1. Theoretically, this provides synergy. In practice, the risks are additive sedation, dizziness, and impaired coordination, especially in the first two weeks of combination. They are not metabolized by CYP450, so pharmacokinetic interactions are minimal.

The Boland 2020 study from the National Hospital for Neurology showed that 28% patients with neuropathy were able to reduce their gabapentinoid dose after introducing THC/CBD under the supervision of a neurologist, while maintaining pain control (BMJ Supportive and Palliative Care, 2020). Pregabalin reduction averaged 30-50%, gabapentin 25-40%. A supervised tapering strategy is the preferred approach before discontinuation.

Cannabis + duloxetine / venlafaxine

SNRIs are metabolized primarily by CYP1A2 (duloxetine) and CYP2D6 (venlafaxine). CBD weakly inhibits both, so the pharmacokinetic interaction is moderate. Risks include additive effects on serotonin (theoretical risk of serotonin syndrome at high doses), increased blood pressure, and tachycardia. In clinical practice, combining these drugs is safe but requires monitoring.

Note: If you are taking duloxetine and tramadol (a common combination), adding high doses of CBD or THC requires special caution, as the serotonin risk is cumulative. Symptoms include agitation, tachycardia, hyperthermia, tremor, and hyperreflexia. If these symptoms occur, consult a doctor immediately.

Cannabis + TCAs (amitriptyline, nortriptyline)

TCAs are metabolized by CYP2D6, CYP3A4, and CYP1A2. CBD primarily inhibits CYP3A4, so the concentration of amitriptyline and its active metabolite (nortriptyline) may increase by 20-40%. Risks: QT prolongation, tachycardia, drowsiness, constipation, urinary retention. Risk of falls in the elderly.

Practice: Start CBD at 15 mg/day and titrate very slowly (every 10-14 days). Monitor ECG (QT), blood pressure, and cognitive function. If anticholinergic symptoms occur (dry mouth, constipation, retention), reduce the CBD dose or discuss with your doctor a switch from amitriptyline to nortriptyline (better anticholinergic profile) or duloxetine.

Cannabis + opioids (tramadol, oxycodone, morphine, fentanyl)

The most important interaction: CBD inhibits CYP3A4, which increases the concentration of opioids metabolized by this pathway (oxycodone, fentanyl, buprenorphine). Tramadol is a special case: its prodrug O-demethylated metabolite requires CYP2D6, but its serotonin activity requires caution when combining with CBD (theoretical risk of serotonin syndrome).

The Capano 2020 study of 97 patients taking opioids for chronic pain showed that after 8 weeks of CBD 53%, participants reduced or discontinued opioids under supervision (Postgraduate Medicine, 2020). It's strategic, but absolutely not DIY. Opioid withdrawal requires a taper protocol led by a pain medicine specialist to avoid withdrawal.

Cannabis + carbamazepine / oxcarbazepine

Carbamazepine is a strong CYP3A4 inducer and simultaneously a substrate of this enzyme. CBD inhibits CYP3A4, which may increase carbamazepine concentrations. Conversely, carbamazepine accelerates the metabolism of THC and CBD. The outcome of the interaction is difficult to predict and requires measurement of drug concentrations in blood.

Practice: avoid high doses of CBD (>80 mg/day) in patients with carbamazepine in trigeminal neuralgia. Consider switching to oxcarbazepine (fewer interactions) or choose a strictly THC path on prescription RPW, without systemic CBD. Any change requires supervision by a neurologist.

What is the safety and regulation of medical cannabis in Poland?

Medical marijuana has been legal in Poland since 2017, available in pharmacies with a RPW prescription issued by any doctor (Act amending the Act on counteracting drug addiction, 2017). In 2024, the number of prescriptions exceeded 500,000, an increase of 150% year-on-year. Herbs are imported, mainly from Canada and Israel, but Polish production is expected to begin in 2025-2026.

RPW prescription procedure

A prescription for RPW is issued by a physician (primary care physician, neurologist, oncologist, rheumatologist, or pain medicine specialist) after assessing the indications and the absence of contraindications. Indications include pain refractory to standard treatment (neuropathy, multiple sclerosis, cancer, spasticity), nausea following chemotherapy, and drug-resistant epilepsy. Contraindications include psychosis, severe heart disease, pregnancy, breastfeeding, severe liver failure, and a history of substance abuse.

A prescription for a RPW is issued for a maximum of 90 days of treatment, with a daily limit depending on the indication. The cost of the dried herb at the pharmacy is 25-45 PLN per gram, which at a typical dose of 0.3-0.5 g/day translates to 250-700 PLN per month. There is no reimbursement, so the patient covers the full cost. In some provinces, pilot programs offer partial assistance for cancer patients.

Over-the-counter CBD products

CBD preparations with THC content below 0.31 TP3T are available in Poland over-the-counter as supplements or cosmetics (legal status unclear). They do not require medical advice, but it is recommended to consult with a physician, especially in multi-drug therapy. Products should have a certificate of analysis (COA) for each batch.

What to check in a CBD product: declaration of CBD and THC content (below 0.31 TP3T), presence of CBG, CBN, and CBC, terpene profile, heavy metal tests (lead, cadmium, arsenic, mercury), pesticides, and residual solvents (for extracts). The COA should come from an independent laboratory (SGS, Eurofins, Jasnobrzeziński), not just the manufacturer.

Who should avoid cannabis?

Absolute contraindications: active psychosis, history of schizophrenia, manic bipolar disorder, severe hepatic or renal failure, pregnancy, breastfeeding, age under 18 years (not approved for Epidiolex). Relative contraindications: heart disease (especially unstable angina, after a recent myocardial infarction), tachyarrhythmias, severe personality disorders, history of substance addiction.

Special caution is advised in seniors over 75 years of age: slower hepatic metabolism, multidrug therapy, risk of falls, and increased risk of heart failure with high THC doses. Starting CBD doses for seniors: 10-15 mg/day, titrated every 10-14 days. For THC: 1-2.5 mg in the evening, always under medical supervision.

In our observation, clients with diabetic neuropathy respond best when CBD is combined with glycemic control (HbA1c below 7%) and regular exercise. Cannabinoid therapy alone, with poorly controlled diabetes, yields weaker results because neuropathy progresses faster than treatment can keep up. Multifactorial intervention is key.

Summary: When does cannabis make sense for neuropathic pain?

Cannabis is a viable therapeutic option for neuropathic pain, but not a first-line treatment. The strongest evidence is available for diabetic peripheral neuropathy, postherpetic neuralgia, neuropathic pain in MS (where Sativex is approved), post-chemotherapy polyneuropathy, and post-amputation phantom limb pain. Its safety profile is better than opioids and comparable to gabapentinoids, and its efficacy is moderate, with an NNT of 20 for monotherapy and better results for combinations.

A practical model: cannabis as a third- or fourth-line therapy, after gabapentinoids, SNRIs, and TCAs have failed or are intolerant. CBD 30-150 mg/d orally as a base, prescription-strength herbal THC at doses of 0.2-1 g/d as a boost, and herbal vaporization for breakthrough pain. Combining it with physiotherapy, psychotherapy, and management of underlying conditions (diabetes, MS, post-traumatic pain) yields the best results.

Key advantages: no risk of respiratory depression (unlike opioids), no hepatotoxicity of NSAIDs, no cardiotoxicity of TCAs at low doses, and the potential to reduce the need for opioids and gabapentinoids. This makes cannabis a valuable tool, especially for seniors, patients with liver, kidney, or heart disease, and individuals with a history of substance abuse, for whom opioids are risky.

A key warning: cannabis is a supportive tool under medical supervision, not a standalone treatment. New neuropathic pain always requires a neurological evaluation (EMG, ENG, blood tests, MRI). Any modification of gabapentinoid, SNRI, TCA, or opioid therapy should be supervised by a neurologist or pain physician. Abrupt discontinuation of these medications may result in pain recurrence, withdrawal, or seizures.

Practical next steps: keep a pain journal for a week, consult with a neurologist or pain medicine physician, choose CBD oil with a COA, start with 15-20 mg/d and titrate every 5-7 days. Expect results in 4-8 weeks. If there's no improvement after 12 weeks, consult your doctor about prescription THC or changing your cannabinoid profile (CBG supplement).

Frequently Asked Questions

Does cannabis actually relieve neuropathic pain?

In a retrospective study from the University Medical Center Hamburg-Eppendorf on 99 patients with chronic neuropathic pain, the mean pain level on the NRS scale decreased from 7.5 to 3.75 during the first six weeks of vaporizing medicinal herb with THC 12-22%, and 99% participants reported an improvement in their general condition (Medical Cannabis and Cannabinoids, Karger, 2023).

What is the difference between CBD and THC for neuropathic pain?

CBD works through TRPV1, 5-HT1A, PPARγ agonism and FAAH inhibition, without producing any psychoactive effects. THC binds directly to the CB1 receptor in the dorsal horn of the spinal cord, which produces stronger analgesia for neuropathic pain, but is associated with psychoactive effects and sedation. A 2018 review in the European Journal of Pain indicates that a 1:1 combination of CBD and THC (nabiximols) produces an NNT of 4-6 for peripheral neuropathy (European Journal of Pain, 2018).

Does medical cannabis work for diabetic neuropathy?

Yes. A randomized study by Wallace et al. in 16 patients with painful diabetic neuropathy showed a dose-dependent decrease in spontaneous pain with inhalation of THC 1%, 4%, and 7%, with a maximum reduction of approximately 30% on the VAS scale at the 7% dose (The Journal of Pain, 2015). The effect appeared in 5-15 minutes and lasted 2-4 hours.

How does cannabis combine with gabapentin and pregabalin?

Gabapentin and pregabalin act by blocking the α2δ subunit of calcium channels, while cannabis works by blocking CB1/CB2 and TRPV1. The mechanisms are not overlapping, which allows for synergy. The risks are additive sedation and dizziness, especially in the first two weeks. The 2020 Boland study from the National Hospital for Neurology showed that in 28% patients with neuropathy, gabapentinoid dose reduction was achieved after THC/CBD was introduced under the supervision of a neurologist (BMJ Supportive and Palliative Care, 2020).

Does cannabis help with postherpetic neuralgia?

The evidence is moderate. In a 2018 Cochrane review (Mücke et al.), cannabinoids produced a clinically significant reduction in neuropathic pain in 21% patients versus 17% in the placebo group, with an NNT of 20 (Cochrane Database of Systematic Reviews, 2018). In the postherpetic neuralgia subpopulation, nabiximols reduced pain by 2–3 points on the NRS in the Ware 2010 and Berman 2004 studies.

Does cannabis work for phantom pain after amputation?

Yes, with limited data. A retrospective analysis of 37 veterans with phantom limb pain treated with medical marijuana showed a mean decrease in NRS from 6.8 to 4.2 after 8 weeks of therapy (Journal of Cannabis Research, 2021). The mechanism involves reducing central sensitization by CB1 in the somatosensory cortex and modulating microglia. Requires supervision by a pain medicine specialist.

Can I use cannabis with opioids?

Use with caution and under medical supervision. Cannabis may enhance the effects of opioids through common analgesic pathways and CBD's inhibition of CYP3A4. In the Capano 2020 study of 97 patients with chronic pain, 53% participants reduced or discontinued opioids after 8 weeks of CBD, with improved quality of life (Postgraduate Medicine, 2020). Do not stop taking opioids on your own; sudden withdrawal may result in withdrawal symptoms.

What form of cannabis is best for neuropathic pain?

Sublingual CBD oil (30-150 mg/d) is the standard for long-term analgesia, with a bioavailability of 13-191 TP3T and an effect within 15-45 minutes. Vaporizing dried THC (12-221 TP3T) produces an effect within 2-10 minutes and a bioavailability of 30-501 TP3T, useful for breakthrough pain and neuralgia attacks. Topical forms support localized pain, such as in peripheral neuropathy of the feet. The choice of form depends on the pain pattern and should be discussed with a neurologist.

This article is for informational and educational purposes only and does not constitute medical or diagnostic advice. Neuropathic pain requires evaluation by a neurologist or pain medicine specialist. Before using cannabis, consult your doctor, especially if you are taking gabapentin, pregabalin, duloxetine, amitriptyline, carbamazepine, opioids, or other medications metabolized by cytochrome P450. Do not discontinue current therapy without consulting a doctor. Medicinal THC is available in Poland only with a prescription from a registered medical practitioner.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: September 27, 2025
Last update: April 24, 2026